ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 6
8
| catalyst
stringlengths 20
963
| label
int64 4
6
|
|---|---|---|---|---|---|
AZN | Neurofibromatosis type 1 plexiform neurofibromas | Approved | 4/13/20 | FDA Approval announced April 13, 2020. | 6 |
GOSS | Eosinophilic asthma | Phase 2b | 10/13/20 | Phase 2b trial did not meet primary endpoint - October 13, 2020. | 4 |
AZN | Risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) | Approved | 5/9/23 | Approved May 9, 2023. | 6 |
ABBV | Upper Limb Spasticity | Approved | 7/29/21 | FDA approval announced July 29, 2021. | 6 |
INFI | Triple negative breast cancer (TNBC) and ovarian cancer | Phase 1 | 12/9/20 | Phase 1 initial data due presented at SABCS Annual Meeting, December 9, 2020. 2/18 response rate (partial responses - PR) for doublet regimen. 5/12 responses for triplet (1 complete response, 4 had a PR). | 5 |
MRK | Renal cell carcinoma | Approved | 4/22/19 | FDA approval announced April 22, 2019. | 6 |
REGN | Stage II to IV Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | 10/16/23 | Phase 2 data from ESMO reported a median duration of follow-up was 18.7 months, and 1 of 10 pts with MPR experienced recurrence, noted October 16, 2023. | 5 |
IONS | C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | 3/28/22 | Phase 1 study did not meet any secondary efficacy endpoints and it did not demonstrate clinical benefit. These results do not support further development, noted March 28, 2022. | 6 |
CYT | Hematologic malignancies, solid tumors, triple negative breast cancer | Phase 1 | 6/30/23 | Phase 1 development discontinued due to dissolution, noted June 30, 2023. | 4 |
SPPI | Non-Hodgkin’s lymphoma | Approved | 9/4/09 | Approved September 4, 2009. | 6 |
PFE | Atopic dermatitis (AD) | Phase 2b | 11/9/20 | Phase 2b trial did not meet primary endpoint - November 9, 2020. Phase 3 trial planned. | 5 |
EGRX | Supraventricular tachycardia (SVT) - atrial fibrillation and atrial flutter | CRL | 5/31/23 | CRL received on May 31, 2023. | 5 |
EWTX | Duchenne Muscular Dystrophy (DMD) | Phase 2 | 10/26/23 | Phase 2 cohort in boys initiated, October 26, 2023. | 5 |
GNFT | Non-alcoholic steatohepatitis (NASH) | Phase 3 | 5/11/20 | Phase 3 data did not meet primary endpoint - May 11, 2020. | 4 |
MEIP | Indolent B-cell Non-Hodgkin's Lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) | Phase 2 | 11/17/22 | Phase 2 data reported a 75.4% objective response rate, and 24.6% of patients achieved a complete response, noted November 17, 2022. | 6 |
CVAC | Solid tumors | Phase 1 | 11/11/22 | Phase 1 data reported that five out of 30 patients (17%) experienced a partial response and no objective responses were observed in the 10 patients of the single-agent cohort, noted November 11, 2022. | 6 |
BHC | Open angle glaucoma (OAG) or ocular hypertension (OHT) | Approved | 11/2/17 | Approval announced November 2, 2017. | 6 |
ATNXQ | Metastatic breast cancer | Phase 3 | 11/22/21 | Phase 3 post hoc analysis showed a median survival rate of 18.9 months in patients treated with Oral Paclitaxel vs 10.1 months in those treated with IV Paclitaxel, with a hazard ratio of 0.59, noted November 22, 2021. | 6 |
ALGS | Nonalcoholic steatohepatitis (NASH) | Phase 1 | 3/29/23 | Phase 1 data presented at the Hepatology Conference demonstrated a favorable safety and pharmacokinetic profile in healthy volunteers and subjects with hyperlipidemia, March 29, 2023. | 6 |
ADVM | Wet age-related macular degeneration (Wet-AMD) | Phase 2 | 11/4/22 | Phase 2 end-of-study results reported that all 2E11 participants were inflammation free at the end of the study, noted November 4, 2022. | 5 |
TAK | Dravet Syndrome / Lennox-Gastaut Syndrome | Phase 3 | 4/27/23 | Phase 3 data reported that 78% of patients tolerated the highest dose level well with sustained reduction in frequency of drop seizures, noted April 27, 2023. | 6 |
SRPT | Duchenne muscular dystrophy | Approved | 2/25/21 | FDA approval announced February 25, 2021. | 6 |
ANAB | Palmo-plantar pustular psoriasis | Phase 2 | 3/8/21 | Phase 2 trial did not meet primary endpoint - March 8, 2021. | 4 |
SLGL | Papulopustular rosacea | Phase 3 | 7/8/19 | Phase 3 top-line data met primary endpoints - July 8, 2019. | 6 |
AGIO | Thalassemia | Phase 2 | 12/12/22 | Phase 2 data reported durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis were observed for up to 72 weeks of treatment in both α- and β-thalassemia patients, noted December 12, 2022. | 6 |
AMGN | KRAS mutant non-small cell lung cancer (NSCLC) | Phase 1/2 | 10/16/23 | Phase 1/2 initial data reported that the confirmed objective response rate (ORR) was 25% (3/12) across efficacy-evaluable patients and seen in both KRAS G12C inhibitor resistant (14.3%; 1/7) and naïve (40%; 2/5) patients, noted October 16, 2023. | 6 |
PFE | Multiple Myeloma | Approved | 8/14/23 | FDA Approved on August 14, 2023. | 6 |
NVS | Non-small cell lung cancer (NSCLC) with BRAF V600E mutation | Approved | 6/22/17 | FDA Approval announced June 22, 2017. | 6 |
PFE | Psoriatic arthritis | Approved | 12/14/17 | Approval announced December 14, 2017. | 6 |
AZN | Acute ischaemic stroke | Approved | 11/6/20 | FDA approval announced November 6, 2020. | 6 |
FHTX | Metastatic Uveal Melanoma (mUM) | Phase 1 | 10/22/23 | Phase 1 clinical data presented at ESMO reported that 1 patient treated at the 7.5 mg QD continuous dose level experienced a DLT of Grade 3 keratitis, noted October 22, 2023. | 6 |
LLY | Chronic kidney disease (CKD) | Approved | 9/22/23 | FDA Approval on September 22, 2023. | 6 |
ERAS | Advanced solid tumors | Phase 1b | 4/18/23 | Phase 1b data presented at AACR showed that dosing was well-tolerated with favorable pharmacokinetics and no apparent drug-drug interactions, noted April 18, 2023. | 6 |
TAK | Hereditary angioedema (HAE) attacks in patients 2 to <6 yrs | Approved | 2/3/23 | FDA approved on February 3, 2023. | 6 |
AZN | Paroxysmal Nocturnal Hemoglobinuria (PNH) - children | Approved | 6/7/21 | FDA approval announced June 7, 2021. | 6 |
ABBV | Mid-Face Injection Via Cannula | Approved | 9/3/19 | FDA Approval announced September 3, 2019. | 6 |
AQST | Epileptic seizures | Approved | 8/31/22 | Tentative approval from FDA on August 31, 2022. The tentative approval was due to to an existing FDA regulatory grant of orphan drug market exclusivity for Valtoco, a diazepam nasal spray product, Libervant is not yet eligible for marketing in the United States. | 6 |
BHC | Acne | Approved | 8/24/18 | FDA Approval announced August 24, 2018. | 6 |
AZN | COVID-19 vaccine | Phase 3 | 3/22/21 | Data from U.S. trial noted 76% efficacy rate - March 24, 2021. | 6 |
FOLD | Epidermolysis Bullosa (EB) | Phase 3 | 9/13/17 | Phase 3 top-line data released September 13, 2017 - endpoints not met. | 4 |
BGNE | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | 9/17/20 | Phase 3 primary endpoint met - PFS 9.7 months in Arm A compared to 7.6 months in the chemotherapy alone Arm B (p=0.0044; stratified hazard ratio [HR]=0.64. | 6 |
BTAI | Solid Tumors | Phase 2 | 10/10/23 | Phase 2 trial showed a median OS of 13.6 months and a 12-month survival rate of 56.5%., noted October 10, 2023. | 6 |
SNY | Cold agglutinin disease | CRL | 11/13/20 | CRL issued November 13, 2020. | 5 |
ALLO | Large B-cell lymphoma | Phase 1 | 6/15/23 | Additional data reported at ICML across all 33 patients the CR rate was 42% with 30% maintaining a CR at Month 6. Results indicated complete responses are more common with lymphodepletion regimens containing 90 mg of ALLO-647 (FCA90). Median duration of response for both the overall population and the patients treated with the Phase 2 regimen (n=12) was 23.1 months, noted June 15, 2023. | 6 |
BCYC | Solid tumors | Phase 1/2 | 2/14/23 | Phase 1/2 data reported a 50% ORR and 75% benefit rate, including one complete response, noted February 14, 2023. | 5 |
REGN | Coronavirus COVID-19 | Phase 3 | 7/2/20 | Phase 3 trial did not meet primary endpoint - July 2, 2020. | 4 |
RMTI | Anemia | Approved | 3/27/20 | FDA approval announced date March 27, 2020. | 6 |
GLPG | Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) | Phase 1/2 | 12/13/22 | Phase 1/2 data reported an ORR of 86% and all responding patients achieved complete response (CR), noted December 13, 2022. | 6 |
JNJ | Reduce the Risk of Recurrent Venous Thromboembolism (VTE) | Approved | 10/14/19 | FDA approval announced October 14, 2019. | 6 |
MGTX | X-Linked Retinitis Pigmentosa | Phase 1/2 | 10/3/20 | Phase 1/2 nine-month data presented at EURETINA 2020 Virtual Meeting October 3, 2020. | 5 |
PASG | GM1 gangliosidosis (GM1) | Phase 1/2 | 8/7/23 | Phase 1/2 initial safety data from cohorts 1-4 up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profile, noted August 7, 2023. | 6 |
PFE | Metastatic colorectal cancer | Approved | 9/28/21 | Approved September 28, 2021. | 6 |
BHC | Psoriasis | Approved | 10/8/18 | Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product. | 6 |
PTCT | SMA type 1/2/3 switching | Phase 2 | 6/11/21 | Phase 2 data reported a sustained >2-fold increase in median SMN protein levels versus baseline in all patients who received prior treatment, noted June 11, 2021. | 6 |
TGTX | Relapsing forms of Multiple Sclerosis (RMS) | Phase 2a | 6/18/18 | Phase 2a updated data released at EAN June 18, 2018. Annualized Relapse Rate (ARR) of 0.07. | 5 |
BMY | Ulcerative Colitis | Approved | 5/27/21 | FDA approval announced May 27, 2021. | 6 |
CLVS | Relapsed ovarian cancer patients with BRCA mutations | Phase 3 | 12/21/20 | Phase 3 trial met primary endpoint - December 21, 2020. | 6 |
VINC | Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Phase 1 | 12/12/22 | Phase 1 data reported that efficacy signals from the 5 newly enrolled pts include 1 stable disease (SD), 2 radiologic disease progression, and 2 on study and who have not yet had first tumor assessment, noted December 12, 2022. | 5 |
FBIO | Non-small cell lung cancer (NSCLC) | Phase 1/2 | 9/25/18 | Phase 1/2 preliminary data released September 24, 2018. | 5 |
NLSP | Narcolepsy | Phase 3 | 3/27/23 | OLE trial data reported that the mean ESS score for these patients declined by approximately 10.2 (SD=5.83) points from their DB study baseline to month 6 in the OLE, noted March 27, 2023. | 5 |
PLUR | Intermittent claudication, or IC | Phase 2 | 6/12/18 | Phase 2 data released June 12, 2018 - primary endpoint met. | 6 |
ADIL | Alcohol use disorder | Phase 3 | 7/11/23 | FDA reviewed the safety data from the ONWARD trial and did not express any concerns with the data, noted July 11, 2023. | 5 |
CINC | Treatment Resistant Hypertension (rHTN) | Phase 2 | 11/7/22 | Phase 2 presentation at AHA reported that iomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol, noted November 7, 2022. | 6 |
ZNTL | Uterine serous carcinoma (USC) | Phase 1 | 6/6/23 | Phase 1 showed an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing, noted June 6, 2022. | 6 |
BIIB | Alzheimer’s disease | Phase 3 | 9/13/19 | Phase 3 trial discontinued due to unfavorable risk-benefit ratio. | 4 |
ITRM | Complicated urinary tract infections (cUTI) | Phase 3 | 6/1/20 | Phase 3 data did not meet primary endpoint - June 1, 2020. | 4 |
JNJ | Newly Diagnosed Multiple Myeloma (NDMM) | Approved | 6/28/19 | FDA Approval announced June 28, 2019. | 6 |
LLY | Type 2 Diabetes | Approved | 5/13/22 | Approved May 13, 2022. | 6 |
SAGE | Bipolar depression | Phase 2 | 7/24/19 | Phase 2 Part A data July 24, 2019 noted MADRS score of 15.5 points at Day 15 (n=23; p<0.0001) - secondary endpoint. | 6 |
AZN | Asthma and comorbid nasal polyps | Phase 3 | 9/5/21 | Phase 3 data showed an 86% reduction in the annualized asthma exacerbation rate (AAER) September 5, 2021. | 6 |
REGN | IgA nephropathy | Phase 2 | 8/29/22 | Phase 2 new results demonstrated an equivalent 36% reduction in 24-hour urine total protein and a higher proportion, 32 vs 13%, of patients treated in comparison to placebo, respectively, achieving greater than or equal to 50% reduction in 24-hour UPCR, noted August 29, 2022. | 6 |
MRK | Solid tumors | Phase 1/2 | 8/9/23 | Phase 1/2 sixth dose escalation cohort data and agent expansion data to showed durable anti-cancer activity observed during monotherapy dose escalation without dose-limiting toxicities. Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11, noted August 9, 2023. | 6 |
ONCY | Colorectal and advanced anal cancers, pancreatic cancer | Phase 1/2 | 11/10/22 | Phase 1/2 data reported a 69% objective response rate (ORR), noted November 11, 2022. | 5 |
GRTX | Pancreatic cancer | Phase 1/2 | 9/8/21 | Phase 1/2 trial final results announced - GC4419 was well tolerated, with similar rates of early and late adverse events in the active and placebo arms September 8, 2021. | 6 |
ASND | Growth Hormone Deficiency - adults | Phase 3 | 9/23/23 | Phase 3 resultspresented at ESPE 2023 showed that the majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit, noted September 23, 2023. | 6 |
LLY | Heart failure with preserved ejection fraction (HFpEF) | Phase 3 | 12/13/19 | Phase 3 data did not meet primary endpoint - December 13, 2019. | 4 |
MRK | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | 9/22/23 | Phase 3 data reported that there was not an improvement in OS for patients who received KEYTRUDA plus LENVIMA compared to docetaxel, noted September 22, 2023. | 6 |
KMDA | Pediatric patients newly diagnosed with type 1 diabetes | Phase 2 | 11/1/17 | Phase 2 data released November 3, 2017. No significant treatment effect noted overall. | 4 |
VIGL | Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) | Phase 1 | 9/11/23 | Phase 2 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg with six-month interim data expected 4Q 2023, noted Septemeber 11, 2023. | 6 |
VRTX | Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation | Approved | 10/21/19 | FDA Approval announced October 21, 2019. | 6 |
SUPN | Epilepsy | Approved | 12/14/18 | FDA approval announced December 14, 2018 to expand label to include monotherapy treatment. | 6 |
ARVN | ER+ positive / HER2- negative breast cancer | Phase 1b | 12/13/21 | Phase 1 dose escalation data reported that treatment was well tolerated with no DLTs at total daily doses up to 700mg, noted December 13, 2021. | 6 |
RHHBY | Castration-resistant prostate cancer | Phase 3 | 6/19/20 | Phase 3 data met one of two co-primary endpoints - June 19, 2020. | 6 |
NVS | Multiple sclerosis (MS) | Approved | 8/25/23 | Approved August 25, 2023. | 6 |
BBIO | Amyloid cardiomyopathy (ATTR-CM) | Phase 3 | 8/27/23 | Phase 3 data presented at ESC reported an 81% survival rate on acoramidis and over 30 months, patients survived more and were hospitalized less than has been seen in prior controlled studies, noted August 27, 2023. | 6 |
NVAX | COVID-19, COVID-19 vaccine, Influenza | Phase 2 | 5/9/23 | Phase 2 data reported that the highest dose stand-alone COVID vaccine candidate achieved statistically significant anti-S IgG and neutralization responses approximately 30% higher than Novavax's prototype COVID vaccine while maintaining comparable safety, noted May 9, 2023 | 6 |
NVS | Fascioliasis | Approved | 2/13/19 | FDA Approval announced February 13, 2019. | 6 |
VTVT | Type 2 Diabetes | Phase 2 | 12/14/16 | Phase 2 primary endpoint met - December 14, 2016. | 6 |
GSK | HIV | Approved | 12/21/21 | Approved December 21, 2021. | 6 |
ZLAB | Ovarian cancer | Approved | 4/29/20 | FDA Approval announced April 29, 2020. | 6 |
VALN | Lyme disease | Phase 2 | 9/7/23 | Phase 2 data showed that participants seroconverted after the booster dose, yielding seroconversion1 rates (SCRs) of 95.3% and 94.6% for all outer surface protein A (OspA) serotypes in all age groups, noted September 7, 2023. | 6 |
KYMR | Peripheral T-cell Lymphoma (PTCL) | Phase 1a | 6/14/23 | Phase 1a data continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed, noted June 14, 2023. | 6 |
MRK | Castration-resistant prostate cancer -first line | Approved | 6/1/23 | FDA Approved on June 1, 2023. | 6 |
BNOX | Social Anxiety Disorder (SAD) | Phase 3 | 10/16/23 | End of Phase 2 meeting minutes resulted in favorable outcome for the company which confirmed agreement with the FDA on its Phase 3 clinical trial expected to commence in 1Q 2024. | 6 |
ADMP | Erectile dysfunction | NDA Filing | 2/26/19 | Refusal to file letter received February 26, 2019. | 5 |
BBIO | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2b | 6/13/22 | Phase 2b treatment data presented at ENDO resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any reported serious adverse events. At week 24 of treatment, 92% (12/13) of participants had achieved normal trough blood calcium levels in the absence of extra-dietary calcium supplements and active vitamin D, and 77% (10/13) of participants had normal urinary calcium excretion | 6 |
AMAM | Breast cancer | Phase 2 | 12/9/22 | Phase 2 safety and efficacy data demonstrated a 57.1% confirmed overall response rate (ORR) with 100% disease control rate (DCR), noted December 9, 2022. | 6 |
BHC | Dry Eye Disease Associated With Meibomian Gland Dysfunction | Phase 3 | 4/13/21 | Phase 3 trial met primary endpoints - April 13, 2021. | 6 |
RARE | Mucopolysaccharidosis 7 (MPS 7) | Approved | 11/15/17 | Approval announced November 15, 2017. | 6 |
PHVS | Hereditary angioedema - prophylactic use | Phase 1 | 11/10/22 | Phase 1 PK data reported that food intake did not have significant effects on the time to reach therapeutic exposure, with no server or serious treatment-emergent adverse events, noted November 10, 2022. | 6 |
Subsets and Splits